

## Publication Acceptance of BrainCool's Thrombectomy Study in Stroke & Vascular Neurology

BrainCool AB's first clinical study in stroke, titled "**CO**m bination of **T**argeted temperature management and **T**hrombectomy after acute **I**schemic **S**troke (COTTIS 1): A feasibility study", focused on combined **T**argeted **T**emperature **M**anagement (TTM) treatment with thrombectomy, has been accepted for publication in the prestigious scientific journal Stroke & Vascular Neurology (with an impact factor of 10, 2023). While the exact publication date is yet to be determined, this milestone marks a significant achievement for our new stroke therapy.

### CEO Martin Waleij comments

-'The scientific publication in Stroke & Vascular Neurology will enhance the credibility and scientific weight of our stroke therapy. The observed results, in part preseteded as well at NeuroRad 2022 (ref 1), demonstrating a doubling in the number of patients achieving survival with good neurological function upon discharge from the hospital, can be considered sensational. The completed clinical study was a safety and feasibility study conducted as preparation for a larger randomized study that is set to commence.

We are thrilled about the recognition and the potential impact this publication will have in advancing stroke therapy.

We will keep you informed of the publication's release date and encourage you to stay tuned for further updates.

Additionally, this publication serves as a solid foundation for the initiation of COTTIS 2, a study that will enroll 400 patients, building upon the findings of the feasibility study".

### Reference 1

[BrainCool AB \(publ\): starka resultat för tidig kylning av trombektomi patienter presenterade på NeuroRad 2022 - BrainCool \(cision.com\)](#)

### Contacts

#### For more information

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

### About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology. BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

**Attachments**

[Publication Acceptance of BrainCool's Thrombectomy Study in Stroke & Vascular Neurology](#)